VIVIO, a Public Benefit Corporation

JPMorgan Chase Faces ERISA Lawsuit: Another Chapter in the Same Story JPMorgan Chase is now facing an ERISA lawsuit, following in the footsteps of Johnson & Johnson and Wells Fargo. For those of us who’ve been in this space long enough, this isn’t shocking—it’s just the same cycle repeating itself. Year after year, companies ignore the importance of transparency and accountability in managing pharmacy benefits. And time after time, it takes a lawsuit to force any real change. So why the sudden wave of lawsuits targeting benefits teams and even board members? Simple: these are the people with the power to choose a better path, yet most continue to double down on the status quo. Maybe that’s because it’s easy to spend someone else’s money. Or maybe, as these lawsuits suggest, some believe the only way to reform the system is by making those in charge personally accountable. Here’s what’s really frustrating: VIVIO has been cited in all three of these lawsuits as the solution that could have prevented employers from overpaying for drugs and exposing themselves to legal risk. We’ve spent years showing employers how they can save billions while ensuring patients get the right treatments—not just the most expensive ones. And yet, despite all the evidence, the vast majority still refuse to act. So, we’ll ask the question again: If employers are getting sued for blindly trusting a broken system, what does that say about the system itself? More importantly, what does it say about those who continue to uphold it? The choice is clear. These companies could have avoided lawsuits—not just by picking a better pharmacy benefits model, but by being on the right side of history. So why wait until the legal system forces your hand? For those interested in the specifics of the JPMorgan Chase lawsuit, here’s a link to the case: https://lnkd.in/gnRWBVJc

Get the latest 3x3x3 Challenges delivered straight to your inbox, like the one featuring VIVIO, a Public Benefit Corporation with Pramod John! Subscribe to the BenefitsAlly Substack for free at BenefitsAlly.com.

💊 Why do Americans pay so much for medications? 💰 Are drugs worth the prices we pay? 📊 How can we measure the true value of a drug? In the latest episode of our podcast #MTVAUnscripted, MTVA Board members Lisa Trumble John Rodis, MD and Steve Schutzer, MD sit down with Pramod John, Chairman & CEO of VIVIO, a Public Benefit Corporation, to unpack these critical questions! Pramod cuts through the complexity of the pharmacy benefit world, bringing a data-driven, no-nonsense approach to understanding drug costs and value. 🗣️ “It’s not the drug that you’re paying for, it’s the outcome.” With #DrugSpending consuming an ever-larger share of U.S. healthcare costs, it’s time to rethink the traditional PBM model. For Pramod, the solution is simple and achievable: We can fix our broken market with a smarter, outcomes-focused approach. 🎧 Don’t miss this insightful and inspiring conversation! Listen now: https://lnkd.in/eiM586NQ #MovingToValueAlliance #PharmacyBenefits #DrugPricing #GLP1s #HealthOutcomes #PBMs #HealthcareTransformation #ValueBasedCare #HealthcareValue #SpecialtyDrugs #HealthcarePodcast

Why are drug prices all over the map—even for the same medication? This Wall Street Journal article reveals how Medicare pays vastly different prices for identical drugs. The issue isn’t about “bad guys” or “good guys” in the PBM world—it’s the PBM model itself that’s broken. Even so-called "transparent" PBMs are part of a system that leads to inconsistent and unpredictable pricing. Here’s the truth: employers don’t have to use a PBM. The current system isn’t mandatory—it’s just the status quo. Read the full article here: https://lnkd.in/gwSuKdXk

Our recent webinar with Mark Cuban on transforming the PBM industry is well worth a watch: https://lnkd.in/gtCf8rGx We're grateful for partners that share our mission to improve healthcare outcomes and affordability. Happy Thanksgiving from your friends at VIVIO! 🦃 #HappyThanksgiving #MarkCuban #PramodJohn #HealthcareInnovation #BetterHealthOutcomes #EmployerBenefits

We are pleased to announce PrecisionCare One™, an extension of VIVIO's proven open-market specialty drug management platform to include all drugs. Read the press release: https://lnkd.in/gNs8SH76 #HealthcareInnovation #PBMDisruption #EmployerBenefits #BetterHealthOutcomes

Join VIVIO, a Public Benefit Corporation, tomorrow for a LIVE Q&A session—the ideal follow-up to today’s impactful webinar, Open Markets, Better Outcomes, Lower Costs, featuring Mark Cuban and Pramod John. Don’t miss this opportunity to dive deeper into the topics that matter most. Register at https://lnkd.in/eXCB-n4B. See you there!

Thanks to everyone who attended the webinar with Mark Cuban today. We are hosting a Post-Webinar Q&A Session as we ran out of time for Q&A. Please attend if you have questions or would like to get into the details of an Open Market replacement for the PBM Model.

𝗪𝗘𝗕𝗜𝗡𝗔𝗥 𝗡𝗼𝘃 𝟮𝟬𝘁𝗵 • 𝟭𝟮𝗣𝗠 𝗘𝗦𝗧 • 𝟵𝗔𝗠 𝗣𝗦𝗧 - 𝘓𝘈𝘚𝘛 𝘊𝘏𝘈𝘕𝘊𝘌 𝘵𝘰 𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 Open Markets, Better Outcomes, Lower Costs: A Discussion with Mark Cuban and Pramod John on Healthcare Innovation PBMs have long claimed to reduce drug costs and enhance healthcare value, but their complex business practices have instead increased medication costs through hidden fees, rebate schemes, and anti-competitive pricing. Operating as expensive intermediaries, they have effectively extracted billions from the healthcare system while failing to deliver on their promise of cost control and value addition to patients and employers. 𝗥𝗘𝗚𝗜𝗦𝗧𝗘𝗥 𝗡𝗢𝗪: https://lnkd.in/gnQsJtbV The success of open markets in reducing costs across industries like retail (Amazon), transportation (Uber, Lyft, Tesla), and travel suggests a similar approach could transform healthcare. While transparent PBMs represent a step in the right direction, there's potential for even more significant improvements through market-based solutions that could help achieve better outcomes at lower costs. Mark Cuban, cofounder of Mark Cuban Cost Plus Drug Company, PBC, believes his transparent pricing model could be his most impactful venture yet. Pramod John, CEO of VIVIO, a Public Benefit Corporation, will introduce VIVIO's PrecisionCare One platform which offers an open market, data-driven alternative to the PBM model. Discover how self-insured companies can fulfill their fiduciary duties while enhancing corporate wellness programs, improving benefits, reducing costs, and delivering better health outcomes for their employees. 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗣𝗼𝗶𝗻𝘁𝘀:  - Right drug, right person, right price, the right outcome – the core mission - The power of open markets - Proof in action: Cost Plus Drugs transformed generics pricing, VIVIO revolutionized specialty drug management - Why PBM contract gibberish like rebate and discount guarantees leads to higher costs - Current PBM practices create legal risks for employers and their fiduciary duties - Replacing PBMs with transparent, open market solutions is possible today Can't make it live? Register anyway, and we’ll send you the webinar recording. 𝗥𝗘𝗚𝗜𝗦𝗧𝗘𝗥 𝗡𝗢𝗪: https://lnkd.in/gnQsJtbV 𝗪𝗵𝗼 𝗦𝗵𝗼𝘂𝗹𝗱 𝗝𝗼𝗶𝗻? This webinar is designed for employers, benefits consultants, employee benefits professionals, the media, and anyone interested in understanding how open markets can transform healthcare. 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗕𝗼𝗻𝘂𝘀: Registrants will be invited to join a special LinkedIn Live follow-up event on November 21 at 1pm EST, 10am PST. #OpenMarketSolutions #HealthcareInnovation #MarkCuban #PramodJohn #EmployeeBenefits